| ORIGINAL ARTICLE |
|
| Year : 2000 | Volume
: 16
| Issue : 2 | Page : 129-133 |
|
|
Intravesical BCG+interferon-α-2b in prevention of recurrence in transitional cell carcinoma of urinary bladder
Nayan K Mohanty, MN Mandal, AN Sinha, Alok K Jha
Departments of Urology and General Surgery, Safdafjang Hospital, New Delhi, India
Correspondence Address:
Nayan K Mohanty
D-II/87. West Kidwai Nagar New Delhi - 110 023
India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Bladder malignancy is the 11th most common cancer in the world with more than 2,00,000 new cases diagnosed every year 90% of these are TCC, of which 75-80% are superficial in nature.
Our aim in this study was to find the efficacy, safety and cost effectiveness of a low dose intravesical imnumotherapy with BCG (70 mg) + Interferon-α-2b in prevention of its recurrence and prolonging disease progression interval.
Between Jan. '94 to Dec. '98, 100 patients with superficial TCC (Ta, TI) of urinary bladder with or without Tis after transurethral resection of tumor underwent intravesical instillation of BCG (70 ing) + Interferon-α-2b (5million IU) weekly for 8 weeks, fortnightly for 8 weeks, monthly . for 8 weeks . followed by maintenance dose at the end of 9th, 12th, 18th & 24th months with follow-up for 60 months.
Results: At the end of 60 months of follow-up 36 patients (36%) showed complete response, 44 patients (44%) showed partial response, resulting in a total response rate of 80% while 20% progressed to higher stage & grade. Patients' tolerance was good and adverse reaction was low 19%.
Conclusion: This study has shown that a low dose combined therapy with BCG and Interferon is not only safe, well tolerated, cost effective but also highly efficient in preventing recurrences in 36%, maintaining superficial nature of the disease in another 44% with a disease progression free interval of 5 years in 80% of cases. |
|
|
|
| [FULL TEXT] [PDF Not available]* |
|
 |
|
